| dc.contributor |
Ifakara Health Research and Development Centre, Ifakara, Tanzania. |
|
| dc.creator |
Mugittu, K |
|
| dc.creator |
Priotto, G |
|
| dc.creator |
Guthmann, J P |
|
| dc.creator |
Kiguli, J |
|
| dc.creator |
Adjuik, M |
|
| dc.creator |
Snounou, G |
|
| dc.creator |
Beck, H P |
|
| dc.creator |
Mshinda, H |
|
| dc.creator |
Olliaro, P |
|
| dc.creator |
Taylor, W R J |
|
| dc.date |
2007-02 |
|
| dc.date.accessioned |
2017-01-31T07:09:35Z |
|
| dc.date.available |
2017-01-31T07:09:35Z |
|
| dc.identifier |
Molecular genotyping in a malaria treatment trial in Uganda - unexpected high rate of new infections within 2 weeks after treatment. 2007, 12 (2):219-23 Trop. Med. Int. Health |
|
| dc.identifier |
1360-2276 |
|
| dc.identifier |
17300628 |
|
| dc.identifier |
10.1111/j.1365-3156.2007.01813.x |
|
| dc.identifier |
http://hdl.handle.net/10144/17720 |
|
| dc.identifier |
http://fieldresearch.msf.org/msf/handle/10144/17720 |
|
| dc.identifier |
Tropical Medicine & International Health |
|
| dc.identifier.uri |
http://dspace.mediu.edu.my:8181/xmlui/handle/10144/17720 |
|
| dc.description |
Polymerase chain reaction (PCR) genotyping of malaria parasites in drug efficacy trials helps differentiate reinfections from recrudescences. A combination therapy trial of one (n = 115) or three (n = 117) days artesunate (1AS, 3AS 4 mg/kg/day) plus sulphadoxine-pyrimethamine (SP) vs. SP alone (n = 153) was conducted in Mbarara, a mesoendemic area of western Uganda. All paired recurrent Plasmodium falciparum parasitaemias on days 7, 14, 21 and 28 post-treatment were genotyped by PCR amplification and analysis of glutamate-rich protein (glurp) and merozoite surface proteins (msp) 1 and 2 genes to distinguish recrudescent from new infections. A total of 156 (1AS = 61, 3AS = 35, SP alone = 60) of 199 paired recurrent samples were successfully analysed and were resolved as 79 recrudescences (1AS = 32, 3AS = 8, SP = 39) and 77 as new infections (1AS = 29, 3AS = 27, SP = 21). The ratios of proportions of new to recrudescent infections were 0.2, 0.9, 1.4 and 1.9 on days 7, 14, 21 and 28, respectively (P < 0.001, chi(2) test for linear trend). Unexpected high new infection rates were observed early in follow-up on days 7 [5/26 (19.2%)] and 14 [24/51 (47.1%)]. These results impact significantly on resistance monitoring and point to the value of genotyping all recurrent infections in antimalarial trials. |
|
| dc.language |
en |
|
| dc.relation |
http://www.blackwell-synergy.com/loi/tmi |
|
| dc.rights |
Archived on this site with the kind permission of Wiley-Blackwell |
|
| dc.title |
Molecular genotyping in a malaria treatment trial in Uganda - unexpected high rate of new infections within 2 weeks after treatment. |
|